№ files_lp_4_process_3_093495
File format: docx
Character count: 176392
File size: 316 KB
The document outlines the contractual terms for the supply, storage, and management of intravenous fluids and medicines, including schedules for different phases of the contract.
Year:
2022
Region / city:
London
Topic:
Contractual terms and conditions for the supply and management of intravenous fluids and licensed medicines
Document type:
Contract
Agency / institution:
Department of Health and Social Care
Author:
The Secretary of State for Health and Social Care
Target audience:
Healthcare suppliers, contractors
Period of validity:
From [insert date] to [insert date]
Approval date:
[insert date]
Amendment date:
[insert date]
Price: 8 / 10 USD
The file will be delivered to the email address provided at checkout within 12 hours.
The file will be delivered to the email address provided at checkout within 12 hours.
Don’t have cryptocurrency yet?
You can still complete your purchase in a few minutes:- Buy Crypto in a trusted app (Coinbase, Kraken, Cash App or any similar service).
- In the app, tap Send.
- Select network, paste our wallet address.
- Send the exact amount shown above.
The final amount may vary slightly depending on the payment method.
The file will be sent to the email address provided at checkout within 24 hours.
The product description is provided for reference. Actual content and formatting may differ slightly.
Year:
2023
Region / City:
Canberra, Australia
Topic:
Paediatric intravenous extravasation management
Document Type:
Guideline
Organization:
Canberra Health Services
Author:
Expert clinical reference groups
Target Audience:
Clinicians in paediatric care
Period of validity:
Ongoing
Approval Date:
7 December 2023
Amendment Date:
26 August 2024
Organisation:
Canberra Health Services
Region:
Canberra, Australian Capital Territory, Australia
Healthcare setting:
Hospital in the Home
Clinical area:
Cardiology
Condition:
Congestive cardiac failure
Patient population:
Adults
Type of document:
Clinical procedure
Route of administration:
Intravenous
Treatment:
Furosemide
Admission criteria:
Defined clinical and general eligibility requirements
Source type:
Institutional clinical guideline
Version:
V3.0
Author:
Dr Julia Sikorska, Consultant Haematologist, STSTN Clinical Guidelines Group
Note:
2019
Executive/Divisional sponsor:
Via Hospital Transfusion Committee
Applies to:
All staff involved in the care of patients with Sickle Cell Disease
Date issued:
V3.0 February 2020
Review date:
February 2023
Approval person/Committee:
Hospital Transfusion Committee
Date:
March 2020
Year:
2020
Region / city:
St George’s, UK
Topic:
Hyperhaemolysis management in Haemoglobinopathies
Document type:
Clinical guidelines
Organization / institution:
St George’s University Hospitals NHS
Target audience:
Healthcare staff involved in the care of Sickle Cell Disease patients
Effective period:
February 2020–February 2023
Approval date:
March 2020
Year:
2022
Region / city:
New South Wales, Australia
Theme:
Medical procedure / MRI contrast agent administration
Document Type:
Standing order
Organization / institution:
New South Wales Health
Author:
NSW Health
Target audience:
Medical professionals, particularly those involved in MRI procedures
Period of validity:
Until approval by hospital/district DTC
Approval date:
Not specified
Date of changes:
Not specified
Note:
Contextual description
Year:
[effective date]
Region / City:
[Facility Location]
Topic:
Intravenous to Oral Antibiotic Conversion
Document Type:
Policy
Organ / Institution:
[Facility Name]
Author:
[Approving individual or committee]
Target Audience:
Clinical staff, healthcare providers
Period of Effectiveness:
[Effective date]
Approval Date:
[Approval Date]
Date of Changes:
[Date of Changes]
Year:
2026
Region / city:
Canberra
Topic:
Clinical Procedures, Healthcare, Intravenous Access
Document Type:
Procedure
Organization / institution:
Canberra Health Services
Author:
Not specified
Target audience:
Healthcare professionals at Canberra Health Services
Effective period:
Ongoing
Approval date:
Not specified
Revision date:
Not specified
Document type:
Medication standing order
Clinical area:
Medical imaging and diagnostic radiology
Patient population:
Adults aged 16 years and over
Medication:
Iohexol iodinated contrast media
Route of administration:
Intravenous injection
Indication:
Contrast-enhanced CT imaging studies
Applicable organisations:
NSW public health organisation imaging departments
Exclusions:
Paediatric patients under 16 years of age
Regulatory framework:
NSW State Form SMR060.160 and PD2013_043 Medication Handling in NSW Public Health Facilities
Authorised personnel:
Registered nurses and accredited medical radiation scientists meeting AHPRA and HETI requirements
Contraindications:
Known hypersensitivity to iodinated contrast media; high-risk renal impairment without medical officer approval
Risk considerations:
Contrast-induced acute kidney injury and hypersensitivity reactions
Guideline references:
RANZCR Iodinated Contrast Media Guideline 2018; ACR Manual on Contrast Media 2018
Approval requirements:
Changes require approval by a radiologist or medical officer
Review requirement:
Annual review for currency
Year:
2021
Region / City:
Canberra
Topic:
Medicine / Cardiology
Document Type:
Guideline
Organization / Institution:
Canberra Health Services
Author:
Not specified
Target Audience:
Healthcare professionals working in CHS
Effective Period:
Not specified
Approval Date:
10 September 2021
Amendment Date:
Not specified
Year:
2023
Country:
Australia
Document type:
Clinical guidance
Organization:
Australian Government Department of Health / Blood Service
Target audience:
Healthcare professionals administering IVIg
Scope:
IVIg administration, safety, and monitoring
Effective from:
April 2023
References:
Criteria for the clinical use of intravenous immunoglobulin in Australia, 3rd edition, October 2018; Product information sheets of Privigen®AU, Kiovig®, Flebogamma®, Gammunex®, Octagam®
Appendices:
Product comparison, infusion rate guides
Date:
March 2023
Country:
Australia
Subject:
Intravenous immunoglobulin administration
Document type:
Clinical practice guidance
Healthcare setting:
Hospital and health services
Target audience:
Healthcare professionals involved in IVIg prescribing and administration
Regulatory context:
BloodSTAR authorization and national IVIg criteria
Products referenced:
Privigen®, Kiovig®, Flebogamma®, Gammunex®, Octagam®, Intragam®10
Effective period:
From April 2023
Clinical scope:
Indications, precautions, preparation, infusion, storage, and adverse effects
Source type:
Official guidance
Year:
2023
Region / City:
Liege, Belgium
Field:
Anesthesia, Pharmacology
Document Type:
Clinical Trial Report
Institution:
Department of Anesthesia and Intensive Care Medicine, Liege University Hospital, Liege, Belgium
Authors:
G Van Munster, F Beck, PY Hardy, M Carella, V Bonhomme
Target Audience:
Medical professionals, researchers in anesthesia
Period of Study:
October 21, 2021 – April 8, 2022
Approval Date:
2021
Modification Date:
N/A
Funding:
Department of Anesthesia and Intensive Care Medicine, Liege University Hospital, Liege, Belgium
Ethics Approval:
Comité d’Ethique Hospitalo-Facultaire Universitaire de Liège (study number 2021/190)
Clinical Trial Registration:
EudraCT: 2021-002824-19
Methodology:
Randomized, Double-blind, Placebo-controlled
Conclusion:
MS does not effectively reduce propofol requirements for hypnosis in general anesthesia during thyroidectomy
Year:
2019
Region / City:
Global
Topic:
Medical Research
Document Type:
Research Study
Institution:
Various research institutions
Author:
Multiple authors
Target Audience:
Healthcare professionals, researchers
Period of Validity:
Ongoing
Approval Date:
2019
Date of Changes:
Not specified
Main Outcome:
Return of spontaneous circulation, survival to hospital discharge, favorable neurological outcome
Comparative Intervention:
Intraosseous vs. Intravenous drug administration during cardiac arrest
Additional Considerations:
Cost, feasibility, health equity
Assessment:
Observational studies
Desirable Effects:
Potential for faster drug delivery
Undesirable Effects:
Risk of reduced drug effectiveness, complications
Certainty of Evidence:
Very low
Resources Required:
No specific study on resource comparison
Cost-Effectiveness:
No included studies
Equity:
IO access may increase health inequity in low-resource settings
Acceptability:
Likely acceptable to stakeholders
Feasibility:
Likely feasible to implement
Program:
Medicare IVIG Demonstration
Administering Agency:
Centers for Medicare & Medicaid Services (CMS)
Country:
United States
Legal Basis:
Medicare IVIG Access and Strengthening Medicare and Repaying Taxpayers Act of 2012
Extended Under:
Disaster Tax Relief and Airport and Airway Extension Act of 2017
Further Extension:
Consolidated Appropriations Act, 2021
OMB Control Number:
0938-1246
CMS Form Number:
CMS-10518
Subject:
Application for beneficiary participation in the IVIG Demonstration
Target Population:
Medicare Part B beneficiaries with primary immune deficiency disease (PIDD)
Enrollment Cap:
6,500 beneficiaries (originally 4,000)
Funding Limit:
$45 million including administrative and evaluation costs
Coverage Scope:
Bundled payment for medically necessary supplies and services for in-home IVIG administration
Application Requirement:
Mandatory signed application by beneficiary and provider
Submission Methods:
Mail or fax
Languages Available:
English and Spanish
Period of Demonstration:
Through December 31, 2023 or until statutory limits are met
Participation Status:
Voluntary; may be terminated by beneficiary at any time
Year:
2023
Region / city:
Australia
Subject:
Pharmaceutical compounding guidelines
Document Type:
Guideline
Organization / Institution:
Pharmacy Board of Australia
Author:
Pharmacy Board of Australia
Target Audience:
Registered pharmacists, education providers, employers
Period of validity:
Indefinite
Approval Date:
Not specified
Date of amendments:
Not specified
Year:
2016
Region / City:
Australia
Topic:
Pharmacy, Medicine Compounding
Document Type:
Consultation Response
Organization:
Pharmaceutical Society of Australia
Author:
Dr Lance Emerson, Chief Executive Officer
Target Audience:
Pharmacists, Pharmacy Regulators
Period of Validity:
Indefinite
Approval Date:
1 February 2016
Date of Amendments:
None
Contextual Description:
Document is a public consultation response discussing terminology issues and proposed updates regarding compounded parenteral medicines, primarily aimed at Australian pharmacists.
Organisation:
Canberra Health Services
Document type:
Guideline
Reference number:
CHS25/225
Jurisdiction:
Australian Capital Territory
Healthcare setting:
Public health services
Subject area:
Medication management
Professional scope:
Nursing and midwifery practice
Approved by:
Drug and Therapeutics Committee
Target professionals:
Registered nurses and registered midwives
Patient groups:
Adults, children 12 years or older, and selected medicines for children under 12 years
Exclusions:
Neonates, Special Care Nursery patients, Neonatal Intensive Care Unit patients
Regulatory framework:
Australian medicines scheduling (Schedules 2, 3, 4, and 8)
Content components:
Governance, safe use, documentation, approved medicine lists
Year:
2023
Region / city:
European Union
Topic:
Pharmaceutical technology development
Document type:
Briefing document
Organization:
European Medicines Agency
Author:
Not specified
Target audience:
Pharmaceutical experts, regulatory authorities
Period of validity:
Not specified
Approval date:
Not specified
Date of modifications:
Not specified
This document is a briefing source for discussing pharmaceutical technology and regulatory aspects at a QIG 1:
1 meeting.
Year:
2023
Country:
Australia
Topic:
Opioid dependence treatment
Document type:
Information overview
Program:
ODT Community Pharmacy Program
Administering body:
Pharmacy Programs Administrator
Related scheme:
Pharmaceutical Benefits Scheme
Legislative framework:
National Health (Highly specialised drugs program) Special Arrangement 2021
Target audience:
Community pharmacists and hospital pharmacists
Effective date:
1 July 2023
Funding period:
2023–24 to 2026–27
Medicines covered:
Methadone, buprenorphine, buprenorphine with naloxone
Regulatory classification:
Schedule 8 controlled drugs
Source type:
Government health program guidance